MEMENTO - A Phase 4, Single-arm, Open-label Clinical Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy to Assess the Impact on Myocardial Structure With Cardiac Magnetic Resonance Imaging (CMR)
Latest Information Update: 22 Sep 2025
At a glance
- Drugs Mavacamten (Primary)
- Indications Hypertrophic cardiomyopathy
- Focus Therapeutic Use
- Acronyms MEMENTO
- Sponsors Bristol-Myers Squibb; MyoKardia
Most Recent Events
- 02 Jul 2025 Planned End Date changed from 31 Jul 2026 to 30 Sep 2026.
- 02 Jul 2025 Planned primary completion date changed from 31 Jul 2026 to 30 Sep 2026.
- 20 Sep 2024 Planned End Date changed from 31 Dec 2026 to 31 Jul 2026.